retatrutide approval status 2025 FDA approves this year? Predictions & Odds 2026 The Effect of Retatrutide on
Description
Glucagon-Like Peptide-1 Receptor Agonists for Major Cardiovascular and Kidney Outcomes in Type 1 Diabetes
When used for overweight or obesity, the drugs are typically prescribed in higher doses than when prescribed for diabetes
The recent SELECT trial examined semaglutide 2.4 mg in people without diabetes but with cardiovascular disease and included biomarker analyses that may provide additional insights
Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial
PMID: 33710717 10 Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice
